Press Release NOTICE OF CAPITAL STOCK VARIATION FILING OF CERTIFICATION PURSUANT TO ART. 2444 C.C. AND UPDATED BYLAWS Bari, July 7, 2026 - Predict S.p.A. (the "Company" or "Predict"), an Innovative SME active in the med-tech sector, specifically in in-vivo diagnostics, through the distribution of ultrasound and radiological equipment and the development of innovative technologies in the breath analysis and digital healthcare sectors, announces the new composition of its share capital resulting from the allocation of 48,000 new ordinary shares following the exercise of 48,000 options related to the "Stock Option Plan 2025-2027" (the "Plan"), approved by the Shareholders' Meeting on April 24, 2025. The aforementioned allocated shares are newly issued shares, in execution of the capital increase for consideration resolved by the Extraordinary Shareholders' Meeting on April 24, 2025, to serve the Plan itself, and are subject to a 30-month lock-up restriction, starting from July 6, 2026. The Company's share capital has therefore been increased for consideration by a total of Euro 842.09, from Euro 134,751.07 to Euro 135,593.16, corresponding to 7,729,000 shares, with no par value, of which 5,869,000 ordinary shares (ISIN IT0005611071), 60,000 PAS shares (ISIN IT0005611097), and 1,800,000 multiple voting shares (ISIN IT0005611089). The new composition of the share capital, fully subscribed and paid up, is reported below, following the certification of the capital increase execution, filed with the competent Companies' Register of Bari, today, in accordance with the law. Current Share Capital Previous Share Capital Variations Euro No. Nominal Value Euro No. Nominal Value Euro No. Total of which: 135,593.16 7,729,000 no par value 134,751.07 7,681,000 no par value 842.09 48,000 Ordinary Shares 102,962.38 5,869,000 102,120.29 5,821,000 842.09 48,000 PAS Shares 1,052.61 60,000 1,052.61 60,000 - - Multiple Voting Shares 31,578.17 1,800,000 31,578.17 1,800,000 - - Pursuant to Article 2436, paragraph 6, of the Civil Code, the updated Bylaws have been filed today, together with the certification of the capital increase execution pursuant to Article 2444 of the Civil Code, with the Companies' Register and are made available at the Company's registered office, on the website www.predictcare.it, Governance/Company Documents section, and on the website of Borsa Italiana S.p.A., Shares/Documents section. Following the allocation of the newly issued shares and pursuant to Article 17 of the Euronext Growth Milan Issuers' Regulation, as well as the latest information in its possession, the Company announces that its shareholder structure is composed as follows:
Shareholder No. Ord. Shares No. PAS Shares3 No. Mult. Voting Shares4 % on Ordinary Shares % on Voting Share Capital % on Total Shares Qo3 S.r.l.1 4,050,000 60,000 1,800,000 69.01% 83.94% 76.47% Treasury Shares 48,000 - - 0.82% 0.42% 0.62% Other shareholders subject to lock-up restrictions2 48,000 - - 0.82% 0.42% 0.62% Market 1,723,000 - - 29.36% 15.21% 22.29% Total 5,869,000 60,000 1,800,000 100.00% 100.00% 100.00% 1. Company attributable for 51% to Angelo Aurelio Gigante and for 49% to Paola Rosa Sciancalepore. 2. 9 shareholders with shares subject to a 30-month lock-up period starting from July 6, 2026. 3. Special category shares issued by the Company, not listed on the Euronext Growth Milan market, which grant the same rights and obligations as Ordinary Shares, except that they are non-transferable and are automatically converted into Ordinary Shares according to the terms and conditions provided for in the company's bylaws. 4. Special category shares issued by the Company, not listed on the Euronext Growth Milan market, which grant the same rights and obligations as Ordinary Shares, except that they grant the right to 3 votes each and are converted into Ordinary Shares according to the rules described in the company's bylaws. Pursuant to Article 26 of the Euronext Growth Milan Issuers' Regulation, the updated shareholder structure is also available in the Investor Relations/Shareholder and Share Capital section of the website www.predictcare.it. The Company will update the shareholder structure and provide timely information should any communications be received from shareholders. **** For the dissemination of regulated information, Predict uses the 1Info dissemination system (www.1info.it), managed by Computershare S.p.A. with registered office in Milan, via Lorenzo Mascheroni 19, and authorized by CONSOB. This press release is available in the Investor Relations/Financial Press Releases section of the website www.predictcare.it and on www.1info.it. About Predict S.p.A. Founded in 2008 in Bari, Predict is an innovative SME dedicated to the development of technologies in the healthcare sector. The Company is organized into four Strategic Business Units (“SBUs”): the Imaging and People Support SBUs offer support for in-vivo diagnostic imaging sectors; the Mistral SBU offers innovative solutions and products in the breath analysis sector, and the Digital Healthcare SBU develops and markets augmented reality and robotics technological solutions for doctors and industry operators. Thanks to its strong propensity for innovation and research, the Company has perfected numerous in-house solutions over the years to improve people's quality of life, such as Mistral, a disruptive diagnostic technology based on breath analysis that allows for non-invasive screening of oncological pathologies and personalized medicine for numerous diseases; Aphel, an artificial intelligence platform for robots, which supports patients and healthcare staff in hospitals and promotes innovative educational environments in schools; Optip, a holopresence communication system for remote medical consultation and training, and, in its Optip Stage version, a holographic stage for shows, events, and educational projects. Thanks to its positioning in the most innovative healthcare sectors, Predict has established long-lasting partnerships with leading university polyclinics and research institutes (IRCCS) in Italy, including: Sapienza University, University of Bari, Polytechnic University of Turin, Polytechnic University of Bari, Giovanni Paolo II Cancer Institute – Bari, IFO National Cancer Institute Regina Elena – Rome, Policlinico Umberto I – Rome. In addition to its headquarters in Bari, Predict opened a secondary office in Milan in November 2025 and a representative office in Rome in April 2026. www.predictcare.it For further information INVESTOR RELATIONS Angelo Ceci Investor Relations Manager E-mail: investor.relator@predictcare.it EURONEXT GROWTH ADVISOR Integrae SIM S.p.A. Piazza Castello 24, 20121 – Milan (MI) E-mail: info@integraesim.it Tel. +39 02 80 50 61 60 INVESTOR RELATIONS ADVISOR KT&Partners Chiara Cardelli ccardelli@ktepartners.com Mob. +39 3387129015 MEDIA RELATIONS Community predict@community.it Titti Ioia – 338 7194998 Claudia Laria – 335 790 4158 Alice Piscitelli - 351 1411998